Indications
Therapeutic Asset Ratings
5,099 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Cyclophosphamide
Metastatic Prostate Carcinoma
Beijing Biotech
P3
B
(61)
Cyclophosphamide
Myeloid Sarcoma
St. Jude Children's Research Hospital
P3
B
(61)
Cyclophosphamide
Non-Cutaneous Melanoma
H. Lee Moffitt Cancer Center and Research Institute
P3
B
(61)
Cytarabine
Acute Myeloid Leukemia With Mutated NPM1
Shen yang
P3
B
(61)
Darolutamide
Prostate Carcinoma
UNICANCER
P3
B
(61)
Dasatinib
Acute Lymphoblastic Leukemia
Nanfang Hospital, Southern Medical University
P3
B
(61)
Denifanstat
Metabolic Dysfunction-Associated Steatohepatitis
Sagimet Biosciences Inc.
P3
B
(61)
Dexasone
T-Cell Adult Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
P3
B
(61)
Dexasone
Cancer
Merck Sharp & Dohme LLC
P3
B
(61)
Dexasone
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
City of Hope Medical Center
P3
B
(61)
Dexasone
Hepatocellular Carcinoma
Shunda Du
P3
B
(61)
Dexasone
Light Chain Deposition Disease
Brigham and Women's Hospital
P3
B
(61)
Docetaxel
Carcinoma Of The Ampulla Of Vater
Minia University
P3
B
(61)
Docetaxel
Ovarian Brenner Tumor
National Cancer Institute (NCI)
P3
B
(61)
Docetaxel
Hypogonadism
SWOG Cancer Research Network
P3
B
(61)
Docetaxel
Head And Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
P3
B
(61)
Docetaxel
Ovarian Serous Adenocarcinoma
Genelux Corporation
P3
B
(61)
Docetaxel
Ovarian Seromucinous Carcinoma
National Cancer Institute (NCI)
P3
B
(61)
Docetaxel
Undifferentiated Ovarian Carcinoma
National Cancer Institute (NCI)
P3
B
(61)
Docetaxel
Renal Cell Carcinoma
NuCana plc
P3
B
(61)
Docetaxel
Triple-Negative Breast Carcinoma
BioLite, Inc.
P3
B
(61)
Donanemab
Central Nervous System Disorder
Eli Lilly and Company
P3
B
(61)
Dostarlimab
Ovarian Carcinoma
University of Washington
P3
B
(61)
Efruxifermin
Metabolic Dysfunction-Associated Steatohepatitis
Akero Therapeutics, Inc
P3
B
(61)
Elafibranor
Primary Biliary Cholangitis
Ipsen
P3
B
(61)
Showing 2026 to 2050 of 5,099 assets
Previous
Page 82 of 204
Next